首页> 美国卫生研究院文献>Haematologica >EZH2 inhibitors abrogate upregulation of trimethylation of H3K27 by CDK9 inhibitors and potentiate its activity against diffuse large B-cell lymphoma

【2h】

EZH2 inhibitors abrogate upregulation of trimethylation of H3K27 by CDK9 inhibitors and potentiate its activity against diffuse large B-cell lymphoma

机译：EZH2抑制剂消除了CDK9抑制剂对H3K27三甲基化的上调作用并增强了其对弥漫性大B细胞淋巴瘤的活性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

获取外文期刊封面目录资料

页面导航

著录项
引文网络
相似文献
相关主题

著录项

期刊名称 Haematologica
作者
Shao Xie; Fan Wei; Yi-ming Sun; Ying-lei Gao; Lu-lu Pan; Min-jia Tan; Shu-dong Wang; Jian Ding; Yi Chen;
展开▼
作者单位

展开▼
年(卷),期 2020(105),4
年度 2020
页码 -1
总页数 11
原文格式 PDF
正文语种
中图分类血液学检验;
关键词

相似文献

外文文献
中文文献
专利

1. EZH2 inhibitors abrogate upregulation of trimethylation of H3K27 by CDK9 inhibitors and potentiate its activity against diffuse large B-cell lymphoma [J] . Shao Xie, Fan Wei, Yi-ming Sun, Haematologica . 2020,第4期

机译：EZH2抑制剂通过CDK9抑制剂删除了H3K27的三甲基化物，并使其对弥漫性大B细胞淋巴瘤的活性
2. ZLD1122, a novel EZH2 and EZH1 small molecular inhibitor, blocks H3K27 methylation and diffuse large B cell lymphoma cell growth [J] . Gao Tiantao, Zhang Lidan, Zhu Yongxia, RSC Advances . 2016,第34期

机译：ZLD1122，一种新型EZH2和EZH1小分子抑制剂，阻断H3K27甲基化和弥漫性大B细胞淋巴瘤细胞生长
3. Quercetin Potentiates the Antitumor Activity of Rituximab in Diffuse Large B-Cell Lymphoma by Inhibiting STAT3 Pathway [J] . Li Xin, Wang Xinhua, Zhang Mingzhi, Cell biochemistry and biophysics . 2014,第2期

机译：槲皮素通过抑制STAT3途径增强利妥昔单抗在弥漫性大B细胞淋巴瘤中的抗肿瘤活性。
4. Expression profile of HIP1R in B-cell subsets and in silico prediction of its functions in diffuse large B-cell lymphoma [C] . Kah Keng Wong, Alison H Banham International Conference on Intelligent Informatics and Biomedical Sciences . 2018

机译：HIP1R在B细胞亚群中的表达特征及其在弥漫性大B细胞淋巴瘤中的功能的计算机预测
5. Modeling Guided Synthesis of Potential Fatty Acid Synthase Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma [D] . Kozlowski, Paige 2015

机译：潜在的脂肪酸合酶抑制剂的建模指导合成，用于治疗弥漫性大B细胞淋巴瘤
6. Voruciclib a clinical stage oral CDK9 inhibitor represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition [O] . Joyoti Dey, Thomas L. Deckwerth, William S. Kerwin, -1

机译：Voruciclib是临床分期口服CDK9抑制剂可抑制MCL-1并使高危弥漫性大B细胞淋巴瘤对BCL2抑制敏感
7. A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma – the STORM trial [O] . Mathias Witzens-Harig, Marie Luise Memmer, Martin Dreyling, 2013

机译：I / II期试验评估挽救疗法的安全性，可行性和活性，该疗法由mTOR抑制剂Temsirolimus联合利妥昔单抗和DHAP的标准疗法组成，用于治疗复发性或难治性弥漫性大细胞B细胞淋巴瘤患者– STORM试用

EZH2 inhibitors abrogate upregulation of trimethylation of H3K27 by CDK9 inhibitors and potentiate its activity against diffuse large B-cell lymphoma

著录项

引文网络

相似文献

相关主题

期刊订阅